In a display of unwavering global commitment, Member States of the World Health Organization (WHO) recently concluded a crucial week-long round of negotiations on a vital annex to the proposed WHO Pandemic Agreement. From February 9 to 14, 2026, delegates convened for the fifth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement, focusing intensely on the draft annex concerning Pathogen Access and Benefit Sharing (PABS). This pivotal component is widely recognized as the cornerstone for establishing a more equitable and effective global response to future pandemics.
The discussions, held under the mandate set by the World Health Assembly (WHA) last year, underscored the collective determination of nations to learn from past global health crises and forge a new path towards collaborative preparedness and response. The PABS annex is designed to address one of the most contentious and critical issues exposed during recent pandemics: the stark disparities in access to life-saving health products, such as vaccines, therapeutics, and diagnostics, particularly between high-income and low-income countries. The overarching goal of the Pandemic Agreement itself is to build a robust international framework that ensures solidarity, equity, and a coordinated approach when the next global health threat inevitably emerges.
The concept of Pathogen Access and Benefit Sharing is multifaceted and complex, yet fundamentally simple in its intent. It seeks to establish a global system where countries experiencing outbreaks promptly share pathogen samples and genetic sequence data with the international scientific community. This timely sharing is indispensable for rapid research and development of countermeasures. In return, the benefits derived from these shared pathogens – specifically, the resulting vaccines, treatments, and diagnostics – must be shared equitably with all nations, especially those that contributed the initial samples and those most vulnerable. This reciprocal arrangement is crucial to prevent a repeat of the 'vaccine apartheid' witnessed during the COVID-19 pandemic, where access to essential tools was heavily skewed towards wealthier nations, leaving billions in developing countries exposed and unprotected.
The 'access' component of PABS mandates that countries detect, assess, and rapidly share biological materials and genetic sequence information of novel pathogens. This proactive sharing allows scientists globally to understand the pathogen's characteristics, track its evolution, and develop effective interventions. Without swift and transparent access to such data, the global health community operates at a significant disadvantage, delaying the development of crucial tools and exacerbating the spread of disease. The annex aims to standardize these processes, ensuring that political or economic barriers do not impede the flow of critical scientific information.
Equally vital is the 'benefit sharing' dimension. This involves concrete mechanisms to ensure that the products developed from shared pathogens are not monopolized. Proposed benefits include guaranteed allocations of vaccines, therapeutics, and diagnostics for countries in need, particularly those with limited manufacturing capacities. It also encompasses technology transfer, allowing developing countries to build their own production capabilities, and intellectual property waivers or compulsory licensing provisions in times of public health emergency. The negotiations grapple with how to operationalize these benefits in a way that is fair, legally sound, and incentivizes innovation while upholding the principle of global equity. Striking this balance is a delicate act, requiring compromise and forward-thinking solutions from all Member States.
Support Nivaran Foundation's global efforts to promote health equity and robust pandemic preparedness worldwide.
Support this work